Cargando…

Trajectory of clinical symptoms in relation to amyloid chronicity

INTRODUCTION: While it is generally appreciated that amyloid precedes symptomatic Alzheimer's disease (AD) by decades, a greater understanding of this timeline may increase prognostic accuracy, planning, and care of persons who are on the AD continuum. METHODS: We examined trajectories of Clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Birdsill, Alex C., Koscik, Rebecca L., Cody, Karly A., Jonaitis, Erin M., Cadman, Robert V., Erickson, Claire M., Chin, Nathaniel A., Przybelski, Robert J., Carlsson, Cynthia M., Asthana, Sanjay, Christian, Bradley T., Eisenmenger, Laura B., Betthauser, Tobey J., Johnson, Sterling C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489232/
https://www.ncbi.nlm.nih.gov/pubmed/36187195
http://dx.doi.org/10.1002/dad2.12360
_version_ 1784792832825884672
author Birdsill, Alex C.
Koscik, Rebecca L.
Cody, Karly A.
Jonaitis, Erin M.
Cadman, Robert V.
Erickson, Claire M.
Chin, Nathaniel A.
Przybelski, Robert J.
Carlsson, Cynthia M.
Asthana, Sanjay
Christian, Bradley T.
Eisenmenger, Laura B.
Betthauser, Tobey J.
Johnson, Sterling C.
author_facet Birdsill, Alex C.
Koscik, Rebecca L.
Cody, Karly A.
Jonaitis, Erin M.
Cadman, Robert V.
Erickson, Claire M.
Chin, Nathaniel A.
Przybelski, Robert J.
Carlsson, Cynthia M.
Asthana, Sanjay
Christian, Bradley T.
Eisenmenger, Laura B.
Betthauser, Tobey J.
Johnson, Sterling C.
author_sort Birdsill, Alex C.
collection PubMed
description INTRODUCTION: While it is generally appreciated that amyloid precedes symptomatic Alzheimer's disease (AD) by decades, a greater understanding of this timeline may increase prognostic accuracy, planning, and care of persons who are on the AD continuum. METHODS: We examined trajectories of Clinical Dementia Rating–Sum of Boxes (CDR‐SB) relative to estimated years of amyloid positivity (A+) in n = 123 participants who were all A+ based on [C‐11]Pittsburgh compound B positron emission tomography. RESULTS: The average amyloid chronicity at CDR‐SB of 2.5 was 20.1 years. The average trajectory of CDR‐SB accelerated after 10 years of elevated amyloid and varied greatly between 10 and 30 years. Exploratory analyses suggested that older age and higher volume of white matter hyperintensities shortened the interval between amyloid onset and cognitive impairment. DISCUSSION: The recontextualization of amyloid burden into the time domain will facilitate studies of disease progression, the influence of co‐pathology, and factors that hasten or slow cognitive impairment.
format Online
Article
Text
id pubmed-9489232
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-94892322022-09-30 Trajectory of clinical symptoms in relation to amyloid chronicity Birdsill, Alex C. Koscik, Rebecca L. Cody, Karly A. Jonaitis, Erin M. Cadman, Robert V. Erickson, Claire M. Chin, Nathaniel A. Przybelski, Robert J. Carlsson, Cynthia M. Asthana, Sanjay Christian, Bradley T. Eisenmenger, Laura B. Betthauser, Tobey J. Johnson, Sterling C. Alzheimers Dement (Amst) Disease Heterogeneity INTRODUCTION: While it is generally appreciated that amyloid precedes symptomatic Alzheimer's disease (AD) by decades, a greater understanding of this timeline may increase prognostic accuracy, planning, and care of persons who are on the AD continuum. METHODS: We examined trajectories of Clinical Dementia Rating–Sum of Boxes (CDR‐SB) relative to estimated years of amyloid positivity (A+) in n = 123 participants who were all A+ based on [C‐11]Pittsburgh compound B positron emission tomography. RESULTS: The average amyloid chronicity at CDR‐SB of 2.5 was 20.1 years. The average trajectory of CDR‐SB accelerated after 10 years of elevated amyloid and varied greatly between 10 and 30 years. Exploratory analyses suggested that older age and higher volume of white matter hyperintensities shortened the interval between amyloid onset and cognitive impairment. DISCUSSION: The recontextualization of amyloid burden into the time domain will facilitate studies of disease progression, the influence of co‐pathology, and factors that hasten or slow cognitive impairment. John Wiley and Sons Inc. 2022-09-20 /pmc/articles/PMC9489232/ /pubmed/36187195 http://dx.doi.org/10.1002/dad2.12360 Text en © 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Disease Heterogeneity
Birdsill, Alex C.
Koscik, Rebecca L.
Cody, Karly A.
Jonaitis, Erin M.
Cadman, Robert V.
Erickson, Claire M.
Chin, Nathaniel A.
Przybelski, Robert J.
Carlsson, Cynthia M.
Asthana, Sanjay
Christian, Bradley T.
Eisenmenger, Laura B.
Betthauser, Tobey J.
Johnson, Sterling C.
Trajectory of clinical symptoms in relation to amyloid chronicity
title Trajectory of clinical symptoms in relation to amyloid chronicity
title_full Trajectory of clinical symptoms in relation to amyloid chronicity
title_fullStr Trajectory of clinical symptoms in relation to amyloid chronicity
title_full_unstemmed Trajectory of clinical symptoms in relation to amyloid chronicity
title_short Trajectory of clinical symptoms in relation to amyloid chronicity
title_sort trajectory of clinical symptoms in relation to amyloid chronicity
topic Disease Heterogeneity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489232/
https://www.ncbi.nlm.nih.gov/pubmed/36187195
http://dx.doi.org/10.1002/dad2.12360
work_keys_str_mv AT birdsillalexc trajectoryofclinicalsymptomsinrelationtoamyloidchronicity
AT koscikrebeccal trajectoryofclinicalsymptomsinrelationtoamyloidchronicity
AT codykarlya trajectoryofclinicalsymptomsinrelationtoamyloidchronicity
AT jonaitiserinm trajectoryofclinicalsymptomsinrelationtoamyloidchronicity
AT cadmanrobertv trajectoryofclinicalsymptomsinrelationtoamyloidchronicity
AT ericksonclairem trajectoryofclinicalsymptomsinrelationtoamyloidchronicity
AT chinnathaniela trajectoryofclinicalsymptomsinrelationtoamyloidchronicity
AT przybelskirobertj trajectoryofclinicalsymptomsinrelationtoamyloidchronicity
AT carlssoncynthiam trajectoryofclinicalsymptomsinrelationtoamyloidchronicity
AT asthanasanjay trajectoryofclinicalsymptomsinrelationtoamyloidchronicity
AT christianbradleyt trajectoryofclinicalsymptomsinrelationtoamyloidchronicity
AT eisenmengerlaurab trajectoryofclinicalsymptomsinrelationtoamyloidchronicity
AT betthausertobeyj trajectoryofclinicalsymptomsinrelationtoamyloidchronicity
AT johnsonsterlingc trajectoryofclinicalsymptomsinrelationtoamyloidchronicity